NGHIÊN CỨU ĐẶC ĐIỂM LÂM SÀNG, CẬN LÂM SÀNG VÀ KẾT QUẢ ĐIỀU TRỊ NỘI KHOA SUY TIM PHÂN SUẤT TỐNG MÁU GIẢM TẠI BỆNH VIỆN ĐA KHOA TRUNG ƯƠNG CẦN THƠ NĂM 2024 - 2025

Abstract

Background: Heart failure (HF) is the final outcome of many cardiovascular diseases. Evidence for the quadruple therapy regimen (ACEi/ARB/ARNI, BB, MRA, SGLT2i) following the 2022 Vietnam Ministry of Health guidelines remains relatively limited. Objectives: To describe clinical and paraclinical characteristics and to review the outcomes of medical treatment in patients with HFrEF at Can Tho Central General Hospital during 2024–2025. Materials and methods: A cross-sectional descriptive study was conducted on 80 patients with HFrEF treated at the Department of Cardiology, Can Tho Central General Hospital during 06/2024-06/2025. Results: Dyspnea on exertion was present in 100% of patients, and pulmonary rales were observed in 58.8%. The mean ejection fraction was 31.46 ± 6.2%, and the mean NT-proBNP level was 18510.68 ± 12176.2 pg/mL. After 12 weeks of treatment, the uptake of the quadruple foundational therapy (ACEi/ARB/ARNI, BB, MRA, and SGLT2i) increased from 6.3% to 20.3%; significant improvements were observed in heart failure symptoms (p<0.001) and signs (p<0.05), whereas changes in NYHA functional class were not statistically significant (p>0.05). Conclusions: Our study of patients with heart failure with reduced ejection fraction (HFrEF) found that dyspnea on exertion and pulmonary rales were the most common clinical manifestations. The mean ejection fraction was 31.46 ± 6.2%, and the mean NT-proBNP level was 18,510.68 ± 12,176.2 pg/mL. After 12 weeks of treatment, increased use of the foundational drug therapy resulted in significant clinical improvement.